Member Info for Rokerpark68

Hi MRK2020,

That's a really interesting post - great information, thank you.

I bought into this too early last year having underestimated the impact of the government's financial support programmes. Anyway, back in profit now having held them all.

I still think it is a good business and it is well-positioned to pick-up what must be increased restructuring and administration activity over the next 12 months.

They have continued with their acquisition programme and have capacity to meet higher levels of business. I don't think FRP will shoot the lights out, but it is a nice counter-cyclical play as government support is gradually reduced.

Still had to laugh when I read the second line of the RNS - they missed out the word application. Their advisers are hopeless.

Hi BMO3,

Yes I remember you doing that. Good to see TILS engaging with UK-CTAP now. Can only help the cause.

Blimey, sorry jh2704.

Hi Happyish,

I never exited in full, but I do think today's Regeneron news obviously makes some sort of MAB collaboration more interesting/likely, especially with Neil Graham now fully embedded at TILS.

I'm of course still bitterly disappointed about the non-delivery of my Accustem shares from last year, but I can't say that too loudly in case MIKODX tells me off again.

I bought back in for a few more today as I was reminded that TILS hired Neil Graham as Chief Medical Officer in January (RNS 13th January 2021). He had 10 years at Regeneron from 2010 to 2020.

More good news this morning - looks like a very progressive JV arrangement with a major player. Just adds to my feeling that Sigmaroc is well-managed and regarded highly within its sector.

I never make specific forecasts regarding share price movements, but Sigmaroc clearly has good business momentum just now, and I can only see it attracting more support in the short-term.

Thanks Rivaldo - that's very encouraging.

I had a another read through the company's 2020 annual report this weekend. It really is informative, well-written and oozes competence.

Hi Noloplus,

The best PR for TILS over the next couple of months would be a successful, attractively-valued IPO of Accustem. This would give the TILS board a big credibility boost and would hopefully attract some serious buyers back to TILS given that it would a very strong statement about GC's and his team's ability to deliver. Everyone in the professional investing community, who after all are the investors with the firepower to really drive the TILS share price if they can find the stock, will be watching the Accustem situation. This is especially the case in the US, where Accustem is being listed.

That would then provide a great backdrop for hopefully some more positive data from the TILS therapeutic portfolio later in the year.

Looks to me like they have, inevitably, had to pay a pretty full price for what does appear to be a good-quality business with some market-leading products in attractive new market segments for VLG.

I'd rather they pay-up for quality assets than look for bargains.

Anyway, we'll get a good feel within the next 12 months whether this really is an attractive deal.

ROCKZ,

I agree we could do with some SP progress. What do you expect will drive it upwards in the short term?

Good news again this morning. I have followed TRIN for several years and have never seen it in better operational or financial shape. Significant management ownership too.

May well add to my holding.

Outstanding results for the FYE 28 February 2021 and a very positive outlook:

"Considering the ongoing momentum and strength of our business, Bloomsbury expects revenue to be ahead and profit to be comfortably ahead of market expectations for the year ended 28 February 2022."

Excellent performance by the company which in my view is still under-rated.

Simon Thompson in the IC today.

MIKODX
As I mentioned the other day I top-sliced at 268p and 168p, so did manage the holding and have ended up square on TILS with my Accustem holding as upside. I still hold a much reduced TILS position for optionality. I am not complaining about the TILS share price, so your comment on that is irrelevant. I can assure you, however, that what happens to Accustem is very relevant to the future of the TILS share price and its fund-raising capability, so I wouldn't be too blase about the topic if I were you.

But I will give it a rest now, although I had thought people might find a broad range of perspectives on TILS useful.

MIKODX
"Time to put Accustem to bed, it's a done deal. Get over it and get over yourself while your (sic) at it."

The point is that it is NOT a done deal because the deal was that it would be IPO'd by 31 December 2020, so this issue will inevitably influence how a lot of investors, especially the larger professional investors, think about TILS until the TILS board / Accustem board deliver on what shareholders voted for in the Demerger Shareholder document back in September 2020.

I have a shed load of Accustem shares which I want value for. So when it's really a done deal I'll get over myself.

I noticed that during Sunday's "broadcast" GC made a comment about needing to hire top people before listing Accustem over the next few months in order to make the IPO more attractive and thereby increase the company's value at IPO.

I must admit, when I heard that, I temporarily lost my customary 'sang froid' on investment matters. Why on earth has is taken an experienced entrepreneur like GC since last October to realise that? Actually, I suspect the board of TILS tried to list Accustem in the UK and the LSE and potential new investors just said "too early, no management team, no company infrastructure, no website/comms, weak advisers, etc etc - get real and come back when you are ready". They didn't like that so then the board decided to focus solely on the US.......

Also, people should understand that the TILS and Accustem boards are essentially the same main people, with the same effectively controlling shareholder, so they think as one.

Finally, as Bluebelly correctly points out, boards of companies, and particularly listed companies, do indeed have a lot of duties and responsibilities towards their shareholders. As we often see in the US, boards who ride roughshod over these can come unstuck.

It was only small.